Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers

Transplant Infectious Disease

Volumn 15, Issue 3, 2013, Pages 300-305

  Chen, G D ^a   Gu, J L ^a   Qiu, J ^a   Chen, L Z ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Kidney transplantation; Outcome; Reactivation; Risk factors

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; GRAFT SURVIVAL; HEPATITIS B VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS CARRIER; VIRUS REACTIVATION;

AGED; CARRIER STATE; DNA, VIRAL; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; VIRUS ACTIVATION;

EID: 84878635506     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12065     Document Type: Article

References (16)

1. Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial 2008; 21 (5): 440-446.
2. Wang C, Sun J, Zhu B, et al. Hepatitis B virus infection and related factors in hemodialysis patients in China - systematic review and meta-analysis. Ren Fail 2010; 32 (10): 1255-1264.
3. Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20 (12): 2013-2017.
4. Reddy PN, Sampaio MS, Kuo HT, et al. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol 2011; 6 (6): 1481-1487.
5. Ahn HJ, Kim MS, Kim YS, et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol 2007; 79 (11): 1655-1663.
6. Ridruejo E, Diaz C, Michel MD, et al. Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. Ann Hepatol 2010; 9 (3): 271-277.
7. Fan WC, King KL, Loong CC, et al. Hepatocellular carcinoma after renal transplantation: the long-term impact of cirrhosis on chronic hepatitis B virus infection. Transplant Proc 2006; 38 (7): 2080-2083.
8. Fabrizi F, Martin P, Dixit V, et al. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5 (12): 2913-2921.
9. Bae E, Park CH, Ki CS, et al. Prevalence and clinical significance of occult hepatitis B virus infection among renal transplant recipients in Korea. Scand J Infect Dis 2012; 44 (10): 788-792.
10. Leung N. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues. Liver Int 2011; 31 (Suppl 1): 85-89.
11. Palumbo E. Lamivudine for chronic hepatitis B: a brief review. Braz J Infect Dis 2008; 12 (5): 355-357.
12. Lapinski TW, Flisiak R, Jaroszewicz J, et al. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005; 11 (3): 400-402.
13. Lee WC, Wu MJ, Cheng CH, et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38 (5): 1074-1081.
14. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 (Suppl 5): 174-184.
15. Lampertico P, Vigano M, Facchetti F, et al. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. Nephrol Dial Transplant 2011; 26 (6): 2037-2041.
16. Tse KC, Yap DY, Tang CS, et al. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant 2010; 24 (2): 207-212.